Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC-3S Phase I/IIa in HIV-1
NCT01549119Phase 2Completed
- Sponsor
- InnaVirVax
- Start
- Feb 2012
- Primary completion
- Feb 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VAC-3S in human immunodeficiency virus type 1 infection (HIV-1), sponsored by InnaVirVax. Started Feb 2012; status: completed.
02
Drugs
VAC-3S
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01549119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01549119.